$ENZN
Enzon Pharmaceuticals Inc Stock $enzn

$enzn Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000114420414015753 Filed on March 14, 2014

Income Statement

Concept	2013 Q4	2013	2012 Q4
Revenue	$7.426M	$34.49M	$10.65M
YoY Change	-30.25%	-19.03%	6.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.240M	$8.800M	$3.230M
YoY Change	-61.61%	-39.31%	-6.92%
% of Gross Profit
Research & Development	$190.0K	$2.715M	$4.330M
YoY Change	-95.61%	-87.0%	-52.83%
% of Gross Profit
Depreciation & Amortization	$0.00	$200.0K	$800.0K
YoY Change	-100.0%	-95.35%	-38.46%
% of Gross Profit
Operating Expenses	$1.430M	$16.33M	$7.570M
YoY Change	-81.11%	-64.92%	-40.16%
Operating Profit		$18.16M
YoY Change		-557.87%
Interest Expense	$0.00	$2.124M	-$1.080M
YoY Change	-100.0%	-60.15%	6.93%
% of Operating Profit		11.7%
Other Income/Expense, Net		$1.553M
YoY Change		-876.5%
Pretax Income	$5.480M	$18.12M	-$9.330M
YoY Change	-158.74%	-361.95%	85.86%
Income Tax	$0.00	-$28.00K	-$4.170M
% Of Pretax Income	0.0%	-0.15%
Net Earnings	$5.479M	$18.15M	-$5.158M
YoY Change	-206.22%	-752.17%	2.75%
Net Earnings / Revenue	73.78%	52.62%	-48.45%
Basic Earnings Per Share	$0.12	$0.41	-$0.11
Diluted Earnings Per Share	$0.12	$0.38	-$0.11
COMMON SHARES
Basic Shares Outstanding		43.78M shares
Diluted Shares Outstanding		51.05M shares

Balance Sheet

Concept	2013 Q4	2013	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.500M	$6.500M	$196.7M
YoY Change	-96.7%	-96.7%	21.05%
Cash & Equivalents	$6.520M	$6.500M	$77.35M
Short-Term Investments	$0.00	$0.00	$119.4M
Other Short-Term Assets	$511.0K	$600.0K	$1.904M
YoY Change	-73.16%	-68.42%	-29.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$7.121M	$7.100M	$198.6M
YoY Change	-96.42%	-96.42%	20.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$0.00	$1.138M
YoY Change	-100.0%	-100.0%	-93.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$0.00	$0.00	$1.138M
YoY Change	-100.0%	-100.0%	-99.36%
TOTAL ASSETS
Total Short-Term Assets	$7.121M	$7.100M	$198.6M
Total Long-Term Assets	$0.00	$0.00	$1.138M
Total Assets	$7.121M	$7.100M	$199.8M
YoY Change	-96.44%	-96.45%	-41.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$93.00K	$100.0K	$776.0K
YoY Change	-88.02%	-87.5%	-51.5%
Accrued Expenses	$1.215M	$1.000M	$5.688M
YoY Change	-78.64%	-82.46%	-58.48%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$115.8M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.308M	$1.300M	$122.3M
YoY Change	-98.93%	-98.94%	699.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$600.0K	$600.0K	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$600.0K	$600.0K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.308M	$1.300M	$122.3M
Total Long-Term Liabilities	$600.0K	$600.0K	$0.00
Total Liabilities	$1.866M	$1.900M	$122.3M
YoY Change	-98.47%	-98.45%	-16.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.7M		-$147.8M
YoY Change	-12.28%
Common Stock	$135.0M		$225.2M
YoY Change	-40.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.255M	$5.300M	$77.47M
YoY Change
Total Liabilities & Shareholders Equity	$7.121M	$7.100M	$199.8M
YoY Change	-96.44%	-96.45%	-41.79%

Cashflow Statement

Concept	2013 Q4	2013	2012 Q4
OPERATING ACTIVITIES
Net Income	$5.479M	$18.15M	-$5.158M
YoY Change	-206.22%	-752.17%	2.75%
Depreciation, Depletion And Amortization	$0.00	$200.0K	$800.0K
YoY Change	-100.0%	-95.35%	-38.46%
Cash From Operating Activities	$3.900M	$14.00M	$6.400M
YoY Change	-39.06%	64.71%	-260.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$800.0K	$121.1M	$27.70M
YoY Change	-97.11%	24.08%	-114.46%
Cash From Investing Activities	$800.0K	$121.1M	$27.70M
YoY Change	-97.11%	24.08%	-114.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-19.90M	-206.0M	-97.70M
YoY Change	-79.63%	54.89%	1893.88%
NET CHANGE
Cash From Operating Activities	3.900M	14.00M	6.400M
Cash From Investing Activities	800.0K	121.1M	27.70M
Cash From Financing Activities	-19.90M	-206.0M	-97.70M
Net Change In Cash	-15.20M	-70.90M	-63.60M
YoY Change	-76.1%	163.57%	-68.28%
FREE CASH FLOW
Cash From Operating Activities	$3.900M	$14.00M	$6.400M
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	$3.900M	$14.00M	$6.400M
YoY Change	-39.06%	65.15%	-260.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	87348000	USD
CY2013	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	89808000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	197181000	USD
CY2011	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	420000	USD
CY2012	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	130000	USD
CY2013	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	12000	USD
CY2011	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	120793000	USD
CY2012	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	31744000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the carrying value of property and equipment, valuation of investments, legal and contractual contingencies, research and development expenses, stock-based compensation, and income taxes. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2011Q4	enzn	Milestone Payment MilestonePayment	5000000	USD
CY2010Q1	enzn	Diposal Of Business Fair Value Amount DiposalOfBusinessFairValueAmount	40900000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2125000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2051000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.99
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.94
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.03
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	10.86
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.90
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.90
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.06
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M6D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y10M6D
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y7M20D
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2013Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.42	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4	pure
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Concentrations of Risk</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At December 31, 2013, the Company had invested none of its cash in financial instruments, nor does it anticipate holding such instruments in the future. In prior periods, holdings of financial instruments, were comprised, principally, of money market funds and debt securities.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	700000	USD
CY2012Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1442000	USD
CY2013Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	85000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	777000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent	332000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	360000	USD
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	150000	USD
CY2012Q4	enzn	Accrued Insurance And Taxes AccruedInsuranceAndTaxes	321000	USD
CY2013Q4	enzn	Accrued Insurance And Taxes AccruedInsuranceAndTaxes	7000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	386000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2012Q4	enzn	Accrued Clinical Trial Current AccruedClinicalTrialCurrent	671000	USD
CY2013Q4	enzn	Accrued Clinical Trial Current AccruedClinicalTrialCurrent	0	USD
CY2012Q4	enzn	Accrued Ligal Current AccruedLigalCurrent	409000	USD
CY2013Q4	enzn	Accrued Ligal Current AccruedLigalCurrent	160000	USD
CY2012Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	324000	USD
CY2013Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	239000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	998000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	242000	USD
CY2013	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	87000	USD
CY2011	enzn	Services Agreement Revenue ServicesAgreementRevenue	100000	USD
CY2012	enzn	Services Agreement Revenue ServicesAgreementRevenue	100000	USD
CY2011	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	600000	USD
CY2011	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.00
CY2013Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.60
CY2013Q4	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.45
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2292000	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	221000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	102000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2125000	shares
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	511000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1904000	USD
CY2013	us-gaap	Payments For Restructuring PaymentsForRestructuring	4648000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77348000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	199781000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7121000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	437000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	441000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	224796000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	134512000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	83000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147848000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129698000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	77468000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5255000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6520000	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	119391000	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2012Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	0	USD
CY2013Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	90000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	198643000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	7121000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1138000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2012Q4	us-gaap	Assets Assets	199781000	USD
CY2013Q4	us-gaap	Assets Assets	7121000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	776000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	93000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5688000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1215000	USD
CY2012Q4	us-gaap	Notes Payable Current NotesPayableCurrent	115849000	USD
CY2013Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	122313000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1308000	USD
CY2012Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	0	USD
CY2013Q4	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	558000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	122313000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1866000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43674170	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44085870	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43674170	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44085870	shares
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	94000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	11000	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	119391000	USD
CY2011	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	200000	USD
CY2012	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	900000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	119308000	USD
CY2013	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	300000	USD
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	38100000	USD
CY2012Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.04	pure
CY2010Q4	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	200000000	USD
	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	16174000	shares
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	153400000	USD
CY2011Q4	us-gaap	Restructuring Reserve RestructuringReserve	4484000	USD
CY2012Q4	us-gaap	Restructuring Reserve RestructuringReserve	777000	USD
CY2012	us-gaap	Payments For Restructuring PaymentsForRestructuring	3468000	USD
CY2012	enzn	Restructuring Reserve Expense Or Adjustment RestructuringReserveExpenseOrAdjustment	-252000	USD
CY2013	enzn	Restructuring Reserve Expense Or Adjustment RestructuringReserveExpenseOrAdjustment	-167000	USD
CY2012	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	13000	USD
CY2013	us-gaap	Restructuring Reserve Accrual Adjustment RestructuringReserveAccrualAdjustment	4943000	USD
CY2013Q4	us-gaap	Restructuring Reserve RestructuringReserve	905000	USD
CY2011Q2	us-gaap	Severance Costs1 SeveranceCosts1	700000	USD
CY2011Q3	us-gaap	Severance Costs1 SeveranceCosts1	2900000	USD
CY2011Q4	us-gaap	Severance Costs1 SeveranceCosts1	1100000	USD
CY2011Q1	us-gaap	Restructuring Charges RestructuringCharges	400000	USD
CY2011Q4	us-gaap	Restructuring Charges RestructuringCharges	1400000	USD
CY2011	us-gaap	Royalty Revenue RoyaltyRevenue	40923000	USD
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	41504000	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	33846000	USD
CY2011	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1431000	USD
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	126000	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	0	USD
CY2011	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	718000	USD
CY2012	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	970000	USD
CY2013	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	647000	USD
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	48072000	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	42600000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	34493000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40180000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20892000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2715000	USD
CY2011	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	926000	USD
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	113000	USD
CY2013	us-gaap	Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross	0	USD
CY2011	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	17281000	USD
CY2012	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	14475000	USD
CY2013	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	8843000	USD
CY2011	us-gaap	Restructuring Charges RestructuringCharges	6025000	USD
CY2012	us-gaap	Restructuring Charges RestructuringCharges	-177000	USD
CY2013	us-gaap	Restructuring Charges RestructuringCharges	4776000	USD
CY2011	us-gaap	Operating Expenses OperatingExpenses	64527000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	46566000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	16334000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-16455000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-3966000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	18159000	USD
CY2011	us-gaap	Investment Income Net InvestmentIncomeNet	1735000	USD
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	2578000	USD
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	534000	USD
CY2011	us-gaap	Interest Expense InterestExpense	5929000	USD
CY2012	us-gaap	Interest Expense InterestExpense	5330000	USD
CY2013	us-gaap	Interest Expense InterestExpense	2124000	USD
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-200000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1553000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20558000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6918000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	18122000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	205000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4135000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-28000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-20763000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-2783000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	18150000	USD
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51910000	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46735000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43782000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51910000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46735000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51045000	shares
CY2011	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2012	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	2.00
CY2013	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	2.05
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-911000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	80000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-83000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21674000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2703000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18067000	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5336000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4263000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	232000	USD
CY2011	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	567000	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	541000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	193000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	3139000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	2119000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	-205000	USD
CY2011	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	240000	USD
CY2012	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	957000	USD
CY2013	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	320000	USD
CY2011	enzn	Amortization Of Purchase Premium On Marketable Securities AmortizationOfPurchasePremiumOnMarketableSecurities	1539000	USD
CY2012	enzn	Amortization Of Purchase Premium On Marketable Securities AmortizationOfPurchasePremiumOnMarketableSecurities	3042000	USD
CY2013	enzn	Amortization Of Purchase Premium On Marketable Securities AmortizationOfPurchasePremiumOnMarketableSecurities	735000	USD
CY2011	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2012	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2013	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1554000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12725000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	8452000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	14005000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	630000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2234000	USD
CY2011	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	104448000	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	305838000	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	115849000	USD
CY2011	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5873000	USD
CY2012	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	130000	USD
CY2013	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12000	USD
CY2011	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1155000	USD
CY2012	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	137000	USD
CY2013	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	283000	USD
CY2011	enzn	Redemptions From Employee Stock Purchase Plan RedemptionsFromEmployeeStockPurchasePlan	167000	USD
CY2012	enzn	Redemptions From Employee Stock Purchase Plan RedemptionsFromEmployeeStockPurchasePlan	24000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	118894000	USD
CY2011	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	263061000	USD
CY2012	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	208267000	USD
CY2013	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-159239000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	97557000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	121128000	USD
CY2011	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	USD
CY2012	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	87348000	USD
CY2013	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	89808000	USD
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	120793000	USD
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	31744000	USD
CY2013	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2011	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000000	USD
CY2012	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	13862000	USD
CY2013	enzn	Redemptions From Employee Stock Purchase Plan RedemptionsFromEmployeeStockPurchasePlan	33000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-121242000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-132985000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-205961000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-293206000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26976000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-70828000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	397530000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104324000	USD
CY2013	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 0in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> </td> <td style="WIDTH: 0.5in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-SIZE: 10pt"><b>(1)</b></font></div> </td> <td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-SIZE: 10pt"><b>Description of Business</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 36.75pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company”) receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of six marketed drug products, namely, PegIntron<sup>®</sup>, Sylatron<sup>®</sup>, Macugen<sup>®</sup>, CIMZIA<sup>®</sup>, Oncaspar and Adagen. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The primary source of the Company’s royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. (“Merck”). The Company currently has no clinical operations and limited corporate operations. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The</font> Company operates in one business segment.</font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Royalty revenues from sales of PegIntron accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 87</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 93</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 94</font>% of the Company’s total royalty revenues in 2013, 2012 and 2011, respectively.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs.   In December 2012, the Company announced that the Company’s  Board of Directors retained Lazard Frères & Co. LLC (“Lazard”) to act as financial advisor in a review of the possible sale or disposition of one or more corporate assets or a sale of the Company and that the Company’s Board of Directors established a special committee to oversee the Company’s sale review process. In connection with the Company’s sale review process, the Company substantially suspended all clinical development activities with a goal of conserving capital and maximizing value returned to the Company’s stockholders.   In April 2013, the Company announced that it had concluded a review of the sale or disposition of one or more corporate assets, or a sale of the Company.   The review did not result in a definitive offer to acquire the Company or all or substantially all of the Company’s assets.   In the same announcement, the Company also announced that its Board of Directors intends to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders. </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In April 2013, pursuant to the terms of an asset purchase agreement, the Company sold to Belrose Pharma, Inc. (“Belrose”), all right, title and interest to the Company’s Customized PEGylation platform and related assets. The assets included (i) intellectual property and know-how associated with the PEGylation platform, (ii) patents and know-how related to PEG- SN-38, (iii) patents and know-how associated with certain of the Company’s internal clinical programs and (iv) certain related supplies and equipment.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">In September 2013, the Company entered into a sublease agreement, which was amended and restated in November 2013, with Axcellerate Pharma, LLC (“Axcellerate”), pursuant to which the Company subleases to Axcellerate a portion of the Company’s premises consisting of approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000</font> rentable square feet of the building located at 20 Kingsbridge Road, Piscataway, New Jersey and a share of related parking areas. The term of the sublease commenced on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">November 14, 2013</font> and will expire on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 30, 2021</font>. The monthly fixed rent payable by Axcellerate to us under the sublease is as follows: (i) in year one, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,417</font>, (ii) in year two, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">15,625</font>, (iii) in year three, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,833</font>, (iv) in year four, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26,042</font> and (v) in each of years five through eight, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font>. The sublease also provides for Axcellerate to pay additional rent to cover its applicable share of real estate taxes, operating expenses, sewer and gas usage, water usage, electricity usage and certain other charges incurred by Axcellerate.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">In October 2013, the Company terminated its License and Collaboration Agreement with Santaris Pharma A/S (“Santaris”) whereby Enzon returned to Santaris the rights to molecules utilizing LNA technology including the mRNA antagonists targeting Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha), the Androgen Receptor (AR), HER3, and Beta-catenin.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1952000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	-484000	USD
CY2013	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging" cellspacing="0" cellpadding="0" width="100%"> <tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"> <td style="WIDTH: 0in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> </td> <td style="WIDTH: 0.5in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-SIZE: 10pt"><b>(3)</b></font></div> </td> <td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"> <div><font style="FONT-SIZE: 10pt"><b>Recently Adopted Accounting Pronouncements</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><b><font style="FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2013, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (ASU 2013-02). ASU 2013-02 requires an entity to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under U.S. GAAP to be reclassified in its entirety to net income. The amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. An entity is required to provide this information together, in one location, either on the face of the statement where net income is presented or as a separate disclosure in the notes to the financial statements. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 did not have a material impact on the Company’s consolidated financial position or results of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The FASB recently issued ASU “Presentation of Financial Statements (Topic 205) Liquidation Basis of Accounting” (ASU 2013-07) that requires an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent, as defined in ASU 2013-7. ASU 2013-7’s objective is to eliminate diverse practices by providing guidance about when and how to apply the model. The guidance applies to all entities except for investment companies regulated under the Investment Company Act of 1940.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">ASU 2013-7 is effective for both public and nonpublic entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. An entity preparing its financial statements on a going-concern basis at the effective date that is required to use the liquidation basis of accounting is required to account for any differences between its existing measurements and the measurements under ASU 2013-7 through a cumulative-effect adjustment. Early adoption is permitted. The Company has evaluated the impact of ASU 2013-7 on the Company’s consolidated financial statements, and has determined that it does not currently have an impact on Company’s consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2013, the FASB issued ASU 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This update amends ASC 740, “Income Taxes,” to require that in certain cases, an unrecognized tax benefit, or portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward when such items exist in the same taxing jurisdiction. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date, and retrospective application is permitted. The Company is currently evaluating the impact this update will have on its consolidated financial statements.  </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	331857000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5453000	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1918000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.343	pure
CY2011	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y1M6D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.015	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.008	pure
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5500000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1900000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.29
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.08
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.24
CY2013Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	1.60
CY2013Q4	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.45
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	868000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	534000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	655000	shares
CY2013	enzn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustment Pursuant To Special Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentPursuantToSpecialDividend	487000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	166000	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	9.06
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	9.47
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	8.77
CY2013	enzn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustment Pursuant To Special Dividend Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentPursuantToSpecialDividendWeightedAverageGrantDateFairValue	8.77
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	8.13
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2000000	USD
CY2011	enzn	Employee Service Share Based Compensation Tax Payments EmployeeServiceShareBasedCompensationTaxPayments	1100000	USD
CY2012	enzn	Employee Service Share Based Compensation Tax Payments EmployeeServiceShareBasedCompensationTaxPayments	100000	USD
CY2013	enzn	Employee Service Share Based Compensation Tax Payments EmployeeServiceShareBasedCompensationTaxPayments	300000	USD
CY2011	enzn	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation	1900000	USD
CY2012	enzn	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation	2000000	USD
CY2013	enzn	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensation	500000	USD
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2217	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3628	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2634	pure
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.3202	pure
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.2634	pure
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2011Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6M
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6M
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6M
CY2011Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6M
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6M
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0020	pure
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0035	pure
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0015	pure
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0012	pure
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0015	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17339	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	17339	shares
CY2013	enzn	Employee Stock Purchase Plan Description EmployeeStockPurchasePlanDescription	The 2007 Employee Stock Purchase Plan (ESPP) permits eligible employees to purchase common stock through payroll deductions which may not exceed 15 percent of the employee’s compensation, as defined, at a price equal to 85 percent of the fair market value of the shares at the beginning of the offering period (grant date) or at the end of the offering period (purchase date), whichever is lower All benefit-eligible employees of the Company may participate in the ESPP other than those who own shares or hold options or nonvested shares representing a combined 5 percent or more of the voting power of the Company’s outstanding stock. The ESPP was terminated on April 1, 2013.
	enzn	Acquisiton Of Inprocess Research And Development And Mile Stone Payment Under License Agreement AcquisitonOfInprocessResearchAndDevelopmentAndMileStonePaymentUnderLicenseAgreement	34000000	USD
CY2011	enzn	Royalties Persuant To Provision In Sales Agreement RoyaltiesPersuantToProvisionInSalesAgreement	500000	USD
CY2007Q3	enzn	Percentage Of Royalty Payable Sold Under Merck Agreement PercentageOfRoyaltyPayableSoldUnderMerckAgreement	0.25	pure
CY2011Q4	enzn	Uncertain Milestone Payment UncertainMilestonePayment	17000000	USD
CY2010	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	27000000	USD
CY2011Q1	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	5000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	703000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	703000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	703000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	742000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2772000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	5623000	USD
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2011	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	4000000	USD
CY2012	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	100000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	56000	USD
CY2013	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.5	pure
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	10601000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	10183000	USD
CY2012Q2	us-gaap	Sales Revenue Net SalesRevenueNet	10231000	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	8056000	USD
CY2012Q3	us-gaap	Sales Revenue Net SalesRevenueNet	11121000	USD
CY2013Q3	us-gaap	Sales Revenue Net SalesRevenueNet	8828000	USD
CY2012Q4	us-gaap	Sales Revenue Net SalesRevenueNet	10647000	USD
CY2013Q4	us-gaap	Sales Revenue Net SalesRevenueNet	7426000	USD
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-1071000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	2390000	USD
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-729000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	4719000	USD
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	4175000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	5562000	USD
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-5158000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	5479000	USD
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	119391000	USD
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1095000	USD
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	24082000	USD
CY2012Q4	enzn	Furniture And Fixtures And Other Gross FurnitureAndFixturesAndOtherGross	1744000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26921000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25783000	USD
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2013Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.08
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2013Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Trading Symbol TradingSymbol	ENZN
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44093515	shares
CY2013	dei	Entity Registrant Name EntityRegistrantName	ENZON PHARMACEUTICALS INC
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000727510
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	86914342	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50500000	USD
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	115849000	USD
CY2012Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	117079000	USD
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	200000	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	186000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	119308000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	119308000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	119391000	USD
CY2011	us-gaap	Depreciation Depreciation	5300000	USD
CY2012	us-gaap	Depreciation Depreciation	4300000	USD
CY2013	us-gaap	Depreciation Depreciation	200000	USD
CY2012	enzn	Stock Repurchased And Retired During Period Average Price Paid Per Share StockRepurchasedAndRetiredDuringPeriodAveragePricePaidPerShare	6.76
	enzn	Stock Repurchased And Retired During Period Average Price Paid Per Share StockRepurchasedAndRetiredDuringPeriodAveragePricePaidPerShare	9.48
CY2013	enzn	Right Expiry Date RightExpiryDate	2012-05-16
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17400000	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17100000	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22000	shares
CY2011	us-gaap	Severance Costs1 SeveranceCosts1	4922000	USD
CY2012	us-gaap	Severance Costs1 SeveranceCosts1	-239000	USD
CY2013	us-gaap	Severance Costs1 SeveranceCosts1	4001000	USD
CY2011	us-gaap	Other Restructuring Costs OtherRestructuringCosts	1103000	USD
CY2012	us-gaap	Other Restructuring Costs OtherRestructuringCosts	62000	USD
CY2013	us-gaap	Other Restructuring Costs OtherRestructuringCosts	775000	USD
CY2012	enzn	Benefits Provided To Existing Employees On Accural Utilization BenefitsProvidedToExistingEmployeesOnAccuralUtilization	200000	USD
CY2013	enzn	Benefits Provided To Existing Employees On Accural Utilization BenefitsProvidedToExistingEmployeesOnAccuralUtilization	32000	USD
CY2011Q4	enzn	Severance Costs For Research And Development Position SeveranceCostsForResearchAndDevelopmentPosition	300000	USD
CY2011Q3	enzn	Restructuring Charges On Lease Termination RestructuringChargesOnLeaseTermination	700000	USD
CY2011	enzn	Sale Of In Process Research And Development SaleOfInProcessResearchAndDevelopment	5000000	USD
CY2012	enzn	Sale Of In Process Research And Development SaleOfInProcessResearchAndDevelopment	0	USD
CY2013	enzn	Sale Of In Process Research And Development SaleOfInProcessResearchAndDevelopment	0	USD
CY2013	enzn	Separation Cost SeparationCost	4000000	USD
CY2011	enzn	General And Administrative Expense Contracted Services GeneralAndAdministrativeExpenseContractedServices	115000	USD
CY2012	enzn	General And Administrative Expense Contracted Services GeneralAndAdministrativeExpenseContractedServices	0	USD
CY2013	enzn	General And Administrative Expense Contracted Services GeneralAndAdministrativeExpenseContractedServices	0	USD
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	11263000	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-61000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-265000	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3506000	USD
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-671000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1334000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2620000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-796000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-683000	USD
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3250000	USD
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-9176000	USD
CY2013	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3877000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	156000	shares
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	30000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-30000	USD
CY2011	enzn	Current State And Foreign Tax Expense Benefit CurrentStateAndForeignTaxExpenseBenefit	205000	USD
CY2012	enzn	Current State And Foreign Tax Expense Benefit CurrentStateAndForeignTaxExpenseBenefit	-4165000	USD
CY2013	enzn	Current State And Foreign Tax Expense Benefit CurrentStateAndForeignTaxExpenseBenefit	2000	USD
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	205000	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-4135000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-28000	USD
CY2011	enzn	Deferred Federal And State Income Tax Expense Benefit DeferredFederalAndStateIncomeTaxExpenseBenefit	0	USD
CY2012	enzn	Deferred Federal And State Income Tax Expense Benefit DeferredFederalAndStateIncomeTaxExpenseBenefit	0	USD
CY2013	enzn	Deferred Federal And State Income Tax Expense Benefit DeferredFederalAndStateIncomeTaxExpenseBenefit	0	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7195000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2421000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	6313000	USD
CY2011	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	205000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	119000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	183000	USD
CY2011	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1339000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2011	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	174000	USD
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2012	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	-26000	USD
CY2013	us-gaap	Income Tax Reconciliation Repatriation Of Foreign Earnings IncomeTaxReconciliationRepatriationOfForeignEarnings	0	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	20000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2672000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8340000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	865000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-6526000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	56329000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	56198000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	25379000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	25379000	USD
CY2012Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6613000	USD
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	USD
CY2012Q4	enzn	Deferred Tax Assets Basis Difference In Fixed Assets DeferredTaxAssetsBasisDifferenceInFixedAssets	4264000	USD
CY2013Q4	enzn	Deferred Tax Assets Basis Difference In Fixed Assets DeferredTaxAssetsBasisDifferenceInFixedAssets	3526000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3165000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3663000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3007000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2518000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax	1560000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax	1530000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	613000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	84000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1167000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1537000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	102097000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	94435000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	102063000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94435000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	34000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	-34000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	34000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	102100000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	94400000	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-671000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1037000	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	144000000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	237000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	-240000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	-957000	USD
CY2013Q1	enzn	Non Employee Chairperson Grants Number Of Times Of Value Of Grants NonEmployeeChairpersonGrantsNumberOfTimesOfValueOfGrants	2	Times
CY2013	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments And Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax	-320000	USD
CY2013Q4	us-gaap	Assets Held For Sale Property Plant And Equipment AssetsHeldForSalePropertyPlantAndEquipment	90000	USD
CY2013	enzn	Employee Stock Purchase Plan Termination Income EmployeeStockPurchasePlanTerminationIncome	4000	USD
CY2013	enzn	Payment To Employee Stock Purchase Plan Termination PaymentToEmployeeStockPurchasePlanTermination	14000	USD
CY2013Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within One Year FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear	130000	USD
CY2013Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Two Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears	193000	USD
CY2013Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Three Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears	258000	USD
CY2013Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Within Four Years FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears	356000	USD
CY2013Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions Thereafter FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter	1505000	USD
CY2013Q4	us-gaap	Future Minimum Sublease Rentals Sale Leaseback Transactions FutureMinimumSubleaseRentalsSaleLeasebackTransactions	2442000	USD
CY2013Q4	enzn	Monthly Fixed Rent Receivable On Sublease Year One MonthlyFixedRentReceivableOnSubleaseYearOne	10417	USD
CY2013Q4	enzn	Monthly Fixed Rent Receivable On Sublease Year Two MonthlyFixedRentReceivableOnSubleaseYearTwo	15625	USD
CY2013Q4	enzn	Monthly Fixed Rent Receivable On Sublease Year Three MonthlyFixedRentReceivableOnSubleaseYearThree	20833	USD
CY2013Q4	enzn	Monthly Fixed Rent Receivable On Sublease Year Four MonthlyFixedRentReceivableOnSubleaseYearFour	26042	USD
CY2013Q4	enzn	Monthly Fixed Rent Receivable On Sublease In Each Of Year Five To Eight MonthlyFixedRentReceivableOnSubleaseInEachOfYearFiveToEight	35000	USD
CY2013Q4	us-gaap	Area Of Land AreaOfLand	30000	sqft
CY2011	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.94	pure
CY2012	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.93	pure
CY2013	enzn	Royalty Revenues From Sales Percentage RoyaltyRevenuesFromSalesPercentage	0.87	pure
CY2011	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	700000	USD
CY2012	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	400000	USD
CY2013	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	100000	USD
CY2013	enzn	Sub Lease Commencement Date SubLeaseCommencementDate	2013-11-14
CY2013	enzn	Sublease Expiration Date SubleaseExpirationDate	2021-07-30
CY2013Q4	enzn	Additional Shares Reserved For Issuance AdditionalSharesReservedForIssuance	1000000	shares
CY2013	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	At December 31, 2013, the Company had federal net operating loss carryforwards of approximately $144.0 million that expire in the years 2020 through 2031 and New Jersey state net operating loss carryforwards of approximately $65.2 million that expire in the years 2029 through 2031. The Company also has federal research and development tax credit carryforwards of approximately $20.8 million for tax reporting purposes that expire in the years 2017 through 2031. In addition, the Company has $4.3 million of state research and development tax credit carryforwards that expire in the years 2015 through 2026.
CY2013	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The Company is currently under examination by the U.S. Internal Revenue Service, with the tax years 2010 through 2011 remaining open to examination. State income tax returns for the states of New Jersey and Indiana are generally subject to examination for a period of 3-4 years after filing of the respective returns. These state income tax returns are not currently under examination. Income tax returns for Canada are generally subject to examination for a period of 3-5 years after filing of the respective return.

Files In Submission

Name	View Source	Status
0001144204-14-015753-index-headers.html	Edgar Link	pending
0001144204-14-015753-index.html	Edgar Link	pending
0001144204-14-015753.txt	Edgar Link	pending
0001144204-14-015753-xbrl.zip	Edgar Link	pending
enzn-20131231.xml	Edgar Link	completed
enzn-20131231.xsd	Edgar Link	pending
enzn-20131231_cal.xml	Edgar Link	unprocessable
enzn-20131231_def.xml	Edgar Link	unprocessable
enzn-20131231_lab.xml	Edgar Link	unprocessable
enzn-20131231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ft0001img-1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v370530_10k.htm	Edgar Link	pending
v370530_ex10-29.htm	Edgar Link	pending
v370530_ex10-30.htm	Edgar Link	pending
v370530_ex10-4.htm	Edgar Link	pending
v370530_ex21-1.htm	Edgar Link	pending
v370530_ex23-1.htm	Edgar Link	pending
v370530_ex23-2.htm	Edgar Link	pending
v370530_ex31-1.htm	Edgar Link	pending
v370530_ex31-2.htm	Edgar Link	pending
v370530_ex32-1.htm	Edgar Link	pending
v370530_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENZN
Enzon Pharmaceuticals Inc Stock $enzn

2013 Q4 Form 10-K Financial Statement

#000114420414015753 Filed on March 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZN Enzon Pharmaceuticals Inc Stock $enzn

2013 Q4 Form 10-K Financial Statement

#000114420414015753 Filed on March 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENZN
Enzon Pharmaceuticals Inc Stock $enzn